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Abstract
This paper aims at predicting lung function values based on pa-
tients historical lung function values and serum biomarkers in Scle-
roderma patients. The progression of disease is measured by three
lung function indexes (FVC, TLC, DLCO). Values of four biomarkers
(TIMP1, P3NP, HA, NT-proBNP) are available. The data are sparse
(6 months intervals) and irregular (many visits are missed). We con-
sider two modeling approaches to achieve our goal, namely, the mixed
effects model which is the standard approach in epidemiological stud-
ies and the functional principal component analysis model which is
typically used for dense temporal datasets. We find that functional
data methodology was able to recover the trajectories of three lung
function indexes and to predict the future values very well.
Keywords: functional principal component analysis, mixed effects model,
prediction, Scleroderma, sparse and irregular functional data.
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1 Introduction
With the introduction of the Electronic Health Records (EHR), it is now
possible to use retrospective information on outcomes, biomakers and clas-
sical risk factors to build a prediction model for a specific outcome. These
models can be used for decision making with regards to planning of hospital
visits, expensive measurements and treatment. Especially for diseases with
heterogeneous trajectories, i.e. where the progress and type of the disease
differ across patients, patient specific prediction is relevant. Unfortunately,
building models from EHR data is often complex. The visits of patients are
typically irregular and sparse and the number of patients with regular ob-
servations might be small. The heterogeneity in disease and underlying risks
needs to be taken into account. Finally the data are typically noisy.
In epidemiology linear mixed models are often used to model the rela-
tionship between biomarkers and a repeatedly measured outcome. Here cor-
relation between measurements for the same person is modeled via random
effects. For mixed effects model theory see Verbeke and Molenberghs (2009),
Hedeker and Gibbons (2006), Wu and Zhang (2006), Wu and Tian (2018)
and the references therein. Forecasting of future disease trajectories based
on the current values of the risk factors, covariates and outcomes might be
performed with these models, see Skrondal and Rabe-Hesketh (2009).
Alternative approaches are in the framework of functional data analysis.
The advantages of these latter methods are that they are very flexible with
regard to the functional model for the outcome over time and they can deal
with irregular and sparse data, see e.g. Beran and Liu (2014, 2016), Peng
and Paul (2009), Yao et al. (2005), James (2010), James et al. (2000). For
general methods and theory on functional data analysis, one may refer to the
monographs such as Ramsay and Silverman (2005), Horvath and Kokoszka
(2012), Kokoszka and Reimherr (2017) and the references therein. In the
FDA framework estimation of future disease trajectories is straightforward,
in contrast to predictions based on a mixed model, which requires integra-
tion over the posterior multivariate distribution of the random effects. On
the other hand, a mixed model provides a straightforward prediction of the
outcome by just filling in the covariate values and zeros for the random ef-
fects. This paper is motivated by an ongoing study on predicting the disease
trajectory of Scleroderma patients. Here we discuss methods for prediction
of expensive measurements based on historical and biomarker data. We will
consider linear mixed models and functional data analysis for this purpose.
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We will build prediction models for Scleroderma disease. Scleroderma
disease is a rare, clinically heterogeneous multisystem disorder which might
affect the patients’ physical and psychological functioning and impairs their
ability to participate in work and social activities (see Jaeger et al. 2017,
Gabrielli et al. 2009, and Muangchan et al. 2013). The disease is hetero-
geneous since only 30% of the patients progress to a severe disease status.
Further the patients can progress to various outcomes. Currently, the most
common outcomes of disease progression include modified rodnan skin score
(mRSS) and three lung functions (FVC, TLC, DLCO) which are age and
gender specific predicted percentages. In this paper, we will not consider
mRSS since it is quite noisy and depends on the observer (see Khanna et
al. 2017 and Clements et al. 1993). Since the lung functions are expen-
sive measurements, good predictions of these functions based on historical
or biomarker data will be valuable. Further, we have data on four candidate
biomarkers, namely TIMP1, P3NP, HA, and NT-proBNP. In the rest of the
paper, we denote TIMP1 by TIMP and NT-proBNP by NT.
Data for this study come from outpatient EHRs of patients attending
Scleroderma clinics every six months. Scleroderma patients visit the hospi-
tal every six months. In our dataset the number of patients with regular
visits is very limited. On the other hand we have a few patients with sev-
eral measurements over a longer time period. To assess prediction accuracy
based on current values of the biomarkers we will use linear mixed models for
a subset of patients with at least two observations at 0, 6, 12 months. Since
the outcomes change continually over time, they are functional data. We
propose therefore to use a functional principal component analysis (FPCA)
method to predict the future values of outcomes. Here we use the subset
of patients who have at least two observations in the first 60 months. Re-
stricted maximum likelihood framework is used to estimate the eigenelements
of underlying covariance operator (see Peng and Paul 2009) and the scores
are estimated by the principal components analysis through conditional ex-
pectation (PACE) method (see Yao et al. 2005). Then the trajectories are
recovered by using the truncated Karhunen-Loe`ve decomposition based on
the estimated eigenelements and scores.
In section 2 we describe the dataset in more detail. In Section 3 we will
introduce the methods. Section 4 presents the results. Finally section 5 is a
conclusion and future research lines are provided.
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2 Dataset
In total, 255 Scleroderma patients with information from hospital visits from
1995 to 2015 have been retrospectively recruited to our study, the majority of
the observations are from after 2010). Data were collected according to eth-
ically approved protocol for observational study HRA number 15/NE/0211.
Typically, the Scleroderma patients visit hospital every six months. How-
ever, many patients missed their appointments or data were not recorded.
Therefore, our dataset has only 573 observations. We have three lung func-
tion indexes FVC, TLC, DLCO with values larger than 0 and small values
for severe disease. Four biomarkers are measured, namely TIMP, P3NP, HA
and NT. After removing the observations with missing values, our dataset
comprises 421 measurements from 208 patients. Further data cleaning results
in 316 measurements from 117 patients see Figure 1 for details.
First for mixed effects models, we select the patients who have at least two
observations at 0, 6, 12 months and the number of patients is 73. Second for
the functional data analysis model, we use all the 117 patients for modelling.
For forecasting, we need patients at least three observations in the first 60
months and the number of patients is 60.
The profiles of these patients with regard to the biomarkers and outcomes
are depicted in Figure 2. Figure 2 also shows that the observations are sparse,
irregular and unbalanced, with more observations in the first two years and
less in the last two years. From these patients, only 60 patients (with 202
measurements) have data for at least three visits. For time 0, i.e. the first
visit time, the mean and covariance of biomarker and outcomes are shown
in Table 1. The correlations between FVC, TLC and DLCO are quite large,
with the largest value of 0.80 for the correlation between FVC and TLC. The
correlations between the biomarkers are smaller and range from 0.15 to 0.44.
3 Methods
Our aim is to predict and forecast the lung functions by using either biomark-
ers or past lung function values. The classical way to analyse sparse longi-
tudinal data is the linear mixed effects model. The grid of visits should be
regular although missing outcomes for some visits are allowed. Alternatively
sparse and irregular longitudinal data are functional data, and forecasting
based on historical outcomes can be performed by using functional principal
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Scleroderma study,
# patients=255, # obs=573
remove NA observations
# patients=208, # obs=421
remove patients with TIMP(t0)
> 500 and TIMP(t0) < 50 ,
# patients=206, # obs=418
remove observations of t > 60,
# patients=206, # obs=416
remove patients with one observation,
# patients=123, # obs=333
remove observations with P3NP > 25,
# patients=123, # obs=332
remove observations with
FVC > 170 and FVC < 50,
# patients=122, # obs=329
remove observations with TLC < 25,
# patients=122, # obs=328
remove observations with DLCO < 120,
# patients=121, # obs=326
remove observations with NT < 1000,
# patients=117, # obs=316
dataset for FDA modelling
patients with at least 2 ob-
servations at 0, 6, 12 months,
# patients=73, # obs=159
dataset for LMM
Figure 1: Patient chart flow.
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Figure 2: Clean data.
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TIMP P3NP HA NT FVC TLC DLCO
mean
234 7 49 130 102 93 65
variance
3188 11 2098 14875 540 329 267
correlation
TIMP 1.00 0.35 0.30 0.21 -0.21 -0.28 -0.19
P3NP 1.00 0.44 0.15 -0.32 -0.35 -0.36
HA 1.00 0.15 0.05 -0.08 -0.04
NT 1.00 -0.08 -0.21 -0.21
FVC 1.00 0.80 0.47
TLC 1.00 0.51
DLCO 1.00
Table 1: At time 0 (112 observations), mean and variance of biomarkers and
outcomes, correlations between biomarkers and outcomes.
component analyses. For our dataset we will consider both methods.
3.1 Linear mixed effects models
To model the relationship between biomarkers and lung function indexes,
linear mixed effects models are fitted to the data from patients with obser-
vations at time 0 (n = 73) and at least one observation at 6 months (n = 42)
or at 12 months (n = 44).
For individual i (i = 1, ..., 73) and measurement j (j = 1, ..., Ni with
Ni ∈ {2, 3} the number of observations for individual i), let yij be the
observation at time tij, xij be the logarithm of the value of the biomarker
for individual i at time tij. Then the following linear mixed effects model is
considered
yij = β0 + β1tij + β2xij + γ0i + γ1itij + eij (1)
where tij = 0, 6 or 12 months, β0j + β1tij is the time specific intercept and
β2j represents the effect of the biomarker at time point tij. The the per-
son specific random intercept γ0i and slope γ1i model follow the following
distribution
(γ0i, γ1i)
T ∼ N(0,Σ)
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with
Σ =
(
σ20 σ01
σ01 σ
2
1
)
.
Finally the term eij is the random residual. Note that since it is expected
that heterogeneity across the patients with regard to disease progress exist
we included a random intercept and slope.
Based on the linear mixed model, a prediction for a new lung function
value can be computed based on current biomarkers by plugging in the mean
of the random effects (i.e. 0) in (1) (see Skrondal and Rabe-Hesketh 2009).
To evaluate the prediction accuracy of this model, the cross validated mean
squared error (MSE) is computed. To this end we base the prediction of the
vector of outcomes yi on the vector of biomarkers xi and a model fitted on
the data set obtained by leaving out the data of indivivual i. Specifically
yˆij = βˆ
(−i)
0 + βˆ
(−i)
1 xij + βˆ
(−i)
2 tij
where βˆ
(−i)
0 , βˆ
(−i)
1 , βˆ
(−i)
2 are the corresponding estimates of β0, β1, β2 of model
(1) on the data set obtained by leaving out the observations of individual i.
Now the leave one out cross validated average MSE is defined as:
MSE =
1∑n
i=1Ni
n∑
i=1
Ni∑
j=1
(yij − yˆij)2.
In principle linear mixed models can also be used to forecast a new mea-
surement in an existing cluster. However since in our dataset we have only
a few patients (n = 13) who have three observations at 0, 6, 12 months,
the performance of these predictions cannot be evaluated. An alternative is
functional principal component analysis.
3.2 Functional principal component analysis
Let Xi(t) be the trajectory of the ith patient, where i ∈ {1, ..., n}, t ∈ [0, 1].
Here the time scale is transformed from 0 to 60 months to [0, 1]. We assume
Xi(t) are independent realizations of a squared integrable random function
X(t) on [0, 1], i.e. X(t) ∈ L2[0, 1]. We denote µ(t) = E[X(t)] the mean
function of X(t) and C(s, t) = E[(X(s)− µ(s))(X(t)− µ(t))] the covariance
function of X(t), then by Mercer’s theorem
C(s, t) =
∞∑
l=1
λlφl(s)φl(t)
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where λ1 ≥ λ2 ≥ ... ≥ 0 with
∑
λl < ∞ are the eigenvalues of C. φl(t)
is the lth eigenfunction corresponding to λl and {φl} forms a complete or-
thonormal basis for L2[0, 1]. Then Xi(t) has the following Karhunen-Loe`ve
decomposition
Xi(t) = µ(t) +
∞∑
l=1
ξilφl(t)
where ξil =
∫
(Xi(t)−µ(t))φl(t)dt is the associated functional principal score
with var(ξil) = λl and φl is also called the lth functional principal compo-
nent. In practice, Xi(t) is usually well approximated by the first L leading
functional principal components and scores
X˜i(t) = µ(t) +
L∑
l=1
ξilφl(t)
For patient i the trajectory Xi(t) is observed at a sparse grid ti1, ...tiNi .
For example, Xi(ti1), .., Xi(tiNi ) are the observed discrete DLCO values for
patient i at time ti1..., tiNi (after rescaling). The number and spacing of the
observed time points vary per patient, i.e. for i 6= j, Ni and Nj might be
different and ti2 − ti1 might be different from tj2 − tj1.
In order to recover the individual-specific curvesXi(t), one has to estimate
the mean function µ(t), FPC scores ξil, FPCs φ(t), and determine the number
of FPCs to be included L. The mean function µ(t) is estimated by a local
linear smoother and it is subtracted from the observations before estimating
the other model parameters.
Since the eigenfunctions corresponding to the largest several eigenvalues
can be well approximated by using less complex basis, cubic B-spline basis
with equally spaced knots is used to expand φl. Under the Gaussianity of
the process, i.e. ξil
iid∼ N(0, λl) and the errors  are normal, the coefficients
of expansion of φl, eigenvalues λl and other nuisance parameters can be
estimated through the restricted maximum likelihood procedure proposed by
Peng and Paul (2009). The number of nonzero eigenvalues and the number of
basis for representing the eigenfunctions are selected by leave-one-curve-out
cross-validation criteria.
Finally, for each patient, we need to estimate the FPC scores. The tradi-
tional way to estimate the FPC scores ξil = 〈Xi−µ, φl〉 is through numerical
integration if the sampling is dense, see e.g. Beran and Liu (2016). However,
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for sparse functional data, numerical integration estimator will not be a rea-
sonable estimate of ξil. Under the Gaussian assumption on the process, the
estimation of FPC scores can be obtained based on conditional expectation
proposed by Mardia et al. (1979) or Yao et al. (2005).
Once obtaining µˆ(t), φˆl(t), ξˆil and the number of nonzero eigenvalues L,
the trajectory of the ith patient can be estimated by
Xˆi(t) = µˆ(t) +
L∑
l=1
ξˆilφˆl(t). (2)
After selecting the number of nonzero eigenvalues L and estimating the
mean curve µˆ(t), the corresponding FPC φˆl(t) and the FPC score ξˆil from
all available data, we can estimate missing values and predict future values
of individual i using the recovered trajectory (2)
Xˆi(t) = µˆ(t) +
L∑
l=1
ξˆilφˆl(t)
where time t can be any past or future time points.
To evaluate the accuracy in forecasting lung function values, the cross
validated mean square error can be computed. For patients who have more
than two observations (n = 60), we predict the last visit value by using all
previous outcomes of this patient and by borrowing the information of all the
other patients (n = 117) using the above FPCA method. Thus to predict
the last value for individual i, the training set on which the model is based,
includes the information of all the patients except for the value of the last
visit of patient i. The forecast is given by
Xˆ
(−last)
i (t) = µˆ
(−last)(t) +
L(−last)∑
l=1
ξˆ
(−last)
il φˆ
(−last)
l (t)
where µˆ(−last)(t) is a local linear estimator of µ(t) with the last value of
individual i being excluded, φˆ
(−last)
l (t) is the estimator of φl(t) with the last
value of individual i being excluded, ξˆ
(−last)
il is the estimator of φl(t) with the
last value of individual i being excluded, L(−last) is the number of nonzero
eigenvalues selected by CV with the last value of individual i being excluded.
Therefore, the estimation of the last value of individual i by using its own
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historical information and all the information of others is given by
Xˆ
(−last)
i (ti,last) = µˆ
(−last)(ti,last) +
L(−last)∑
l=1
ξˆ
(−last)
il φˆ
(−last)
l (ti,last)
where ti,last is the last visiting time for individual i.
To assess the accuracy of the forcasts the mean squared errors are com-
puted, i.e.
MSE =
1
n
n∑
i=1
(xi − xˆi)2.
for observations are x1, ..., xn and corresponding prediction values are xˆ1, ..., xˆn.
Finally the coefficient of determination R2 which assesses the importance
of the improvement in fit from the simpler model is computed:
R2 = 1− MSE1
MSE0
,
where MSE1 and MSE0 are the MSE for the model based on the historical
values and the null model, respectively.
Finally we assess whether the biomarkers have an effect on the forcast.
We regress the residuals of the predicted values of the three outcomes (FVC,
TLC, DLCO), i.e. ri,ti,last = Xi(ti,last) − Xˆ(−last)i (ti.last), on the observed
values of the biomarker zi,ti,last at last time points for the patients who have
at least three observations (n = 60). Specifically, we consider the simple
linear regression
ri,ti,last = α + βzi,ti,last + i
and denote the estimated intercept and slope as αˆ and βˆ respectively. Then
the residuals are estimated as rˆi,ti,last = αˆ + βˆzi,ti,last . We then compute our
updated predicted value as
Xˆi(ti.last) = Xˆ
(−last)
i (ti.last) + rˆi,ti,last
Notice that for NT, the logarithm transformation is used.
4 Results
4.1 Linear mixed effects models
For each combination of lung function index (FVC, TLC, DLCO) and biomarker
(TIMP, P3NP, HA, NT), linear mixed model (1) is fitted. Table 2 shows the
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p-values of the chi-square tests which compare the model with the biomarker
to the null model without a biomarker. It appears that there is not much
evidence for an association between the biomarkers and the lung function
indexes. Only the effect of P3NP on DLCO is statistically significant at the
5% level.
TIMP P3NP HA NT
FVC 0.25 0.21 0.68 0.99
TLC 0.87 0.61 0.38 0.37
DLCO 0.13 0.02 0.85 0.52
Table 2: The p-values for the effects of the biomarkers on the outcomes.
For each lung function biomarker combination, the leave one out cross
validated average MSE of the prediction based on the mixed effects model is
given in Table 3. Here, also the leave one out cross validated average MSE of
the prediction is given based on a mixed effects model without the biomarker
(null model). It appears that the mixed effects models including one of the
biomarkers only slightly improve the prediction compared to the null model.
The largest improvement is 5.3 % for the combination of P3NP on DLCO.
TIMP P3NP HA NT null
FVC 644 646 654 650 649
TLC 405 400 405 401 401
DLCO 306 300 320 318 317
Table 3: The cross validated MSE’s for predictions based on various model.
Null is the model without a biomarker, i.e. only time is included in the mixed
effects model
4.2 Functional principal component analysis
The estimated mean functions of the outcomes (FVC, TLC, DLCO) decrease
during the whole period of five years (see Figure 3). Note that we rescaled
the 60 months into a [0, 1] interval. All the biomarkers increase in the first
two to three years. During the last two to three years, the biomarkers P3NP,
HA and NT have a decreasing trend. At the end of the interval the estimate
of the curves for the biomarkers appears to be uncertainty, which is probably
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caused by the lack of sampling points at the end of the interval (see Figure
2).
The mean function for mRSS has a decreasing trend. Note, however, that
the measurement error is around 5 points, hence the slight decrease is not
medical relevant and we may assume that the mean function is constant over
time.
We used two or three principal components to approximate the individual
curves. Figure 4 displays the curves for the first 10 patients for TIMP,
P3NP, HA, NT, FVC, TLC, and DLCO (from bottom to top). Overall, the
trajectories for each patient captures the behavior of the observations. For
the batches of blue lines, the recovered cures fluctuate due to the shape of
the mean functions (see Figure 3).
In order to quantify the prediction performance of our FPCA model,
the predicted values of the last visit are computed. We only predicted the
last values of the patients who have at least three measurements (n = 60
patients). Figure 5 shows the prediction results. Here the blue points are the
predicted values, and the black points are the observed values. The length
of the red bars are the prediction errors. We observe that in general the
predictions are good, however for patients who had a long period between
the last and the previous visit and for time points in the second half of the
time interval, the prediction error appears to be larger. This is probably due
to lack of information to predict this value.
The cross validated MSE’s for the prediction are shown in Table 4. The
cross validated MSE for the null model, i.e. prediction of the last value by the
average of the 60 patients is also provided. Compared to the null model, our
model has a much smaller cross validated MSE. In addition the improvement
in prediction using historical data is better (90% reduction in MSE) than
the improvement in prediction by using the biomarkers in the mixed-effects
model (1% reduction in MSE) (Table 3). Table 4 also shows the MSE for the
subgroup of patients who have a time interval of less than six months between
the last and previous visit (near) (41 out of 60 patients) and the remaining
patients (far) (19 out of 60 patients). We also considered the cross validated
MSE in the subgroup of patients who have their last visit in the first 24
months (early) (36 out of 60 patients) and the remaining patients (late) (24
out of 60 patients). The MSE for “near” and “early” groups are smaller for
most outcomes than for “far” and “late” group, because for these groups more
information (more visits and more patients) is available. For TLC, there is
not much difference between “early” and “late” groups. However, there is a
13
Figure 3: Mean.
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Figure 4: Trajectory.
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Figure 5: Prediction.
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difference between “near” and “far” groups, where the ”far” group performs
better. The reason is that for the “near” group the variation between the last
two observations in each individual is quite large. Our model has difficulties
in capturing this since we used the B-spline basis. Finally the coefficient
of determinations are given in Table 4. Here the smallest coefficient is 0.87
(DLCO).
MSE R2
null full near far early late full
# patients 60 60 41 19 36 25 60
FVC 538 39 32 53 23 62 0.93
TLC 327 27 31 20 28 27 0.92
DLCO 244 32 22 55 21 49 0.87
Table 4: Results of forecasting the outcomes of 60 patients using functional
data analysis. Reported are MSE and R2. The “null” model is the prediction
of the last value using the average of the 60 patients. “near” corresponds to
the group which have their last observation within a period of six months
after the previous visit, “far” comprises the rest of the patients. “early”
corresponds to the subgroup of patients which has the last observation time
within the first 24 months of disease onset, “late” comprises the rest of the
patients.
Finally we investigated whether the biomarkers can further improve the
prediction performance of our model. A linear regression model was fitted
where the residuals of our model are regressed on the current biomarker
values. The p-values for the regression coefficients are shown in Table 5. It
appears that the biomarkers, P3NP, HA and NT are associated with the
prediction of DLCO based on the historical data. The biomarker NT is
associated with the prediction of FVC and TLC based on their historical
values. The MSEs and the R2 values for the updated predictions are also
given in Table 5. It appears that the predictions are only slightly improved.
Thus the biomarkers do not improve the prediction either when added to the
null model or to the model based on the historical data.
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TIMP P3NP HA NT
p-values
FVC 0.807 0.365 0.578 0.034
TLC 0.589 0.865 0.627 0.032
DLCO 0.819 0.013 0.012 0.069
MSE
FVC (39) 38 38 38 35
TLC (27) 27 27 27 25
DLCO (32) 32 29 29 31
R2
FVC 0.00 0.04 0.03 0.10
TLC 0.00 0.00 0.00 0.07
DLCO 0.00 0.09 0.09 0.03
cross validated MSE
FVC (39) 40 40 40 39
TLC (27) 29 29 30 28
DLCO (32) 35 32 31 34
Table 5: Results of the methods which include the biomarker information
of the last time point in the forecast model based on patients historical
observations. Reported are p-values to assess association and MSE and R2
to assess prediction performance.
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5 Discussion
In this paper we considered two methodological approaches to predict new
lung function values using candidate biomarkers and patient’s historical in-
formation on these lung functions measured for Scleroderma patients. We
considered linear mixed models to assess the predictive value of the biomark-
ers. Linear mixed models are popular for the analysis of data from epidemi-
ological studies. However data from EHR are irregular. Indeed in our study
we could only analyze data from 73 patients with regular observations, while
we had 117 patients in total. Unfortunately to forecast new values based on
historical information using mixed models was not possible since we do not
have sufficient patients with more than two regular observed values. There-
fore for forecasting based on historical data, we considered functional data
analysis methods.
With regards to the biomarkers we obtained some evidence for association
between the biomarkers P3NP, HA and NT with the three lung functions
DLCO (all three) and FVC and TLC (HA and NT). However the added
predictive value to the null model and to the model with historical data was
small. It might be that our models are too simple to capture the relationship
between the biomarkers and the outcomes. More advanced methods are
needed to model non linear relationships or a delayed effect of the biomarker
on the outcome. Unfortunately, the dataset was too small to investigate this
kind of models.
Forecasting based on historical data using functional data analysis meth-
ods performed well. The cross validated MSEs of these models were much
smaller than the cross validated MSEs of the null model. Especially for time
intervals less than or equal to six months and in the first two years after
disease onset, estimation of the lung function values was good. It is expected
that when more data are available even better predictions can be obtained
for the whole disease trajectory if the time gaps are not too large. Further
improvements of prediction accuracy might be obtained by including the
biomarker trajectories in the regression part instead of only the last values,
by joint modelling of the three correlated lung functions and by considering
a model based on a mixture approach with as unobserved status the mem-
bership of the group which will develop the disease (30% of the patients).
A drawback of functional data analysis methods is that it is not likeli-
hood based. Hence parameter estimates might be biased if we have data
missing at random. In this study we have no drop out so we expect that
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our estimates are unbiased. For studies with drop outs, inverse probability
weighting (Kurland and Heagerty, 2006) might be a solution.
To conclude we successfully applied functional data analyses methods to
forecast new lung function values based on historical data. These methods
are relevant since lung function measurements are expensive. Moreover ap-
plications of these methods might result in less visits to the hospital which
improves quality of life of Scleroderma patients. Further in the future im-
provements might be obtained by development of new methodology for a
larger group of patients with a longer follow up time.
References
[1] Beran, J. and Liu, H. (2014). On estimation of mean and covariance
functions in repeated time series with long-memory errors. Lithuanian
Mathematical Journal, 54(1), 8-34.
[2] Beran, J. and Liu , H. (2016). Estimation of eigenvalues, eigenvectors
and scores in FDA models with dependent errors. Journal of Multivariate
Analysis, 147, 218-233.
[3] Clements, P.J., Lachenbruch, P.A., Seibold, J.R., Zee, B., Steen, V.D.,
Brennan, P., ... and Massa, M. (1993). Skin thickness score in systemic
sclerosis: an assessment of interobserver variability in 3 independent stud-
ies. The Journal of rheumatology, 20(11), 1892-1896.
[4] Gabrielli, A., Avvedimento, E.V., and Krieg, T. (2009). Scleroderma.
New England Journal of Medicine, 360(19), 1989-2003.
[5] Hedeker, D., and Gibbons, R. D. (2006). Longitudinal data analysis (Vol.
451). John Wiley & Sons.
[6] Horvath, L. and Kokoszka, P. (2012). Inference for functional data with
application. Springer Science and Business Media.
[7] Kokoszka, P. and Reimherr, M. (2017). Introduction to functional data
analysis. CRC Press.
[8] Kurland, B.F. and Heagerty, P.J. (2005). Directly parameterized regres-
sion conditioning on being alive. Biostatistics, 6, 241-258.
20
[9] Jaeger, V. K., Distler, O., Maurer, B., Czirjak, L., Lorand, V., Valentini,
G., ... and Nihtyanova, S. (2017). Functional disability and its predictors
in systemic sclerosis: a study from the DeSScipher project within the
EUSTAR group. Rheumatology, 57(3), 441-450.
[10] James, G. (2010). Sparseness and functional data analysis. The Oxford
Handbook of Functional Data Analaysis, 298-323.
[11] James, G., Hastie, T., and Sugar, C. (2000) Principal Component Mod-
els for Sparse Functional Data, Biometrika 87, 587-602.
[12] Khanna, D., Furst, D. E., Clements, P. J., Allanore, Y., Baron, M.,
Czirjak, L., ... and Mayes, M. (2017). Standardization of the modified
Rodnan skin score for use in clinical trials of systemic sclerosis. Journal
of scleroderma and related disorders, 2(1), 11.
[13] Mardia, K. V., Kent, J. T., and Bibby, J. M. (1979). Multivariate Anal-
ysis. Academic Press.
[14] Muangchan, C., Baron, M., Pope, J., and Canadian Scleroderma Re-
search Group. (2013). The 15% rule in scleroderma: the frequency of
severe organ complications in systemic sclerosis. A systematic review.
The Journal of rheumatology, jrheum-121380.
[15] Peng, J. and Paul, D. (2009). A geometric approach to maximum likeli-
hood estimation of the functional principal components from sparse lon-
gitudinal data. Journal of Computational and Graphical Statistics, 18(4),
995-1015.
[16] Ramsay, J.O. and Silverman, B.W. (2005). Functional Data Analysis
(Second Edition).
[17] Skrondal, A. and RabeHesketh, S. (2009). Prediction in multilevel gen-
eralized linear models. Journal of the Royal Statistical Society: Series A
(Statistics in Society), 172(3), 659-687.
[18] Verbeke, G. and Molenberghs, G. (2009). Linear Mixed Models for Lon-
gitudinal Data. Springer, New York.
[19] Wu, C. O. and Tian, X. (2018). Nonparametric Models for Longitudinal
Data: With Implementation in R. Chapman and Hall/CRC.
21
[20] Wu, H. and Zhang, J. T. (2006). Nonparametric regression methods for
longitudinal data analysis: mixed-effects modeling approaches (Vol. 515).
John Wiley & Sons.
[21] Yao, F., Mu¨ller, H. G. and Wang, J. L. (2005). Functional data analysis
for sparse longitudinal data. Journal of the American Statistical Associ-
ation, 100(470), 577-590.
22
